By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase I clinical study evaluating HLX97, a small molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B), for the treatment of advanced/metastatic solid tumors in mainland China.
Clinical Development Milestone
| Item | Detail |
|---|---|
| Company | Shanghai Henlius Biotech Inc. (HKG: 2696) |
| Trial Phase | Phase I |
| Patient Status | First patient dosed |
| Therapeutic Area | Advanced/metastatic solid tumors |
| Geography | Mainland China |
| Next Steps | Dose escalation and safety assessment |
Drug Profile & Mechanism of Action
- Molecule: Small molecule inhibitor targeting epigenetic regulators
- Target: Lysine acetyltransferase 6A/B (KAT6A/B) enzymes
- Innovation: KAT6A/B work with paralog KAT6B and other chromatin-associated proteins to acetylate lysine residues on histone H3, playing an oncogenic role across multiple tumor types
- Development Stage: Early clinical (Phase I)
Strategic Context
Henlius Biotech, primarily known for its biosimilars portfolio, is strategically expanding into novel targeted oncology therapies. The initiation of this Phase I trial represents a significant milestone in the company’s diversification beyond biosimilars into innovative assets addressing high-unmet medical needs in oncology.
The KAT6A/B inhibition approach offers a novel epigenetic strategy for cancer treatment, potentially providing new therapeutic options for patients with limited alternatives in advanced solid tumor settings.
Market Outlook
- Oncology Landscape: Epigenetic targets like KAT6A/B represent an emerging frontier in precision oncology with potential applicability across multiple tumor types
- Competitive Position: HLX97 joins a limited number of KAT6A/B inhibitors in clinical development globally
- Pipeline Strategy: This program complements Henlius’s existing oncology pipeline, which includes both biosimilars and novel targeted agents
- Development Timeline: Preliminary data from the dose-escalation phase expected within 12-18 months
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines and therapeutic potential of HLX97. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, and competitive dynamics.-Fineline Info & Tech